Nyxoah Raises $3 Million from its At-the-Market Equity Offering Read more about Nyxoah Raises $3 Million from its At-the-Market Equity Offering
Nyxoah Raises $3 Million from an At-the-Market Equity Offering Read more about Nyxoah Raises $3 Million from an At-the-Market Equity Offering
Nyxoah Announces a $15 Million Private Placement Financing Read more about Nyxoah Announces a $15 Million Private Placement Financing
Nyxoah Announces Achievement of Key Clinical and Regulatory Milestones Read more about Nyxoah Announces Achievement of Key Clinical and Regulatory Milestones
Nyxoah Files Shelf Registration Statement and Announces At-the-Market Equity Offering Program Read more about Nyxoah Files Shelf Registration Statement and Announces At-the-Market Equity Offering Program
Nyxoah Receives FDA IDE Approval to Initiate the ACCCESS Study of Genio® in Complete Concentric Collapse Patients Read more about Nyxoah Receives FDA IDE Approval to Initiate the ACCCESS Study of Genio® in Complete Concentric Collapse Patients
Nyxoah Announces CE-Mark Indication Approval to Treat Complete Concentric Collapse (CCC) Patients Read more about Nyxoah Announces CE-Mark Indication Approval to Treat Complete Concentric Collapse (CCC) Patients
Nyxoah Announces U.S. FDA Breakthrough Device Designation Granted for the Genio® System for Obstructive Sleep Apnea and Complete Concentric Collapse Read more about Nyxoah Announces U.S. FDA Breakthrough Device Designation Granted for the Genio® System for Obstructive Sleep Apnea and Complete Concentric Collapse
Nyxoah to Release First Half 2021 Financial Results on August 31 and Host Earnings Conference Call on September 1, 2021 Read more about Nyxoah to Release First Half 2021 Financial Results on August 31 and Host Earnings Conference Call on September 1, 2021
Nyxoah Announces Closing of Nasdaq Initial Public Offering and Underwriters’ Full Exercise of Option to Purchase Additional Shares Read more about Nyxoah Announces Closing of Nasdaq Initial Public Offering and Underwriters’ Full Exercise of Option to Purchase Additional Shares